Beihai Gofar Chuanshan Biological Co., Ltd. (SHA:600538)
China · Delayed Price · Currency is CNY 7.36
-0.04 (-0.54%)
Feb 6, 2026, 3:00 PM CST
SHA:600538 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 313.9 | 338.3 | 367.06 | 457.25 | 421.98 | 264.9 |
Other Revenue | 2.16 | 2.16 | 2.09 | 2.44 | 2.73 | 2.8 |
| 316.06 | 340.47 | 369.15 | 459.68 | 424.72 | 267.7 | |
Revenue Growth (YoY) | -9.53% | -7.77% | -19.69% | 8.23% | 58.65% | 6.59% |
Cost of Revenue | 242.92 | 254.68 | 279.46 | 332.98 | 316.59 | 201.84 |
Gross Profit | 73.14 | 85.78 | 89.7 | 126.71 | 108.12 | 65.86 |
Selling, General & Admin | 82.61 | 86.58 | 90.44 | 85.93 | 83.08 | 60.42 |
Research & Development | 7.79 | 8.06 | 12.62 | 8.22 | 9.14 | 0.05 |
Other Operating Expenses | 3.26 | 2.95 | 3.33 | 3.17 | 3.67 | 2.5 |
Operating Expenses | 94.12 | 101 | 111.05 | 102.18 | 98.71 | 63.85 |
Operating Income | -20.98 | -15.21 | -21.35 | 24.53 | 9.42 | 2.01 |
Interest Expense | -2.92 | -2.34 | -0.37 | -0.51 | -0.53 | -0.11 |
Interest & Investment Income | 13.73 | 2.63 | 3.58 | 17.38 | 4 | 7.5 |
Currency Exchange Gain (Loss) | -0.05 | -0.05 | -0.07 | -0.35 | 0.71 | - |
Other Non Operating Income (Expenses) | -0.69 | -3.23 | -1.59 | -0.51 | 0.1 | 0.01 |
EBT Excluding Unusual Items | -10.91 | -18.2 | -19.8 | 40.54 | 13.7 | 9.4 |
Impairment of Goodwill | -60.21 | -60.21 | -55.43 | - | - | - |
Gain (Loss) on Sale of Investments | 0.26 | -11.34 | -2.66 | -0.27 | -0.85 | -1.81 |
Gain (Loss) on Sale of Assets | -2.74 | -2.71 | -0.08 | 0.07 | -0.02 | -0.04 |
Asset Writedown | -0.66 | - | -1.4 | - | -0.41 | - |
Other Unusual Items | 0.47 | 0.47 | 1.81 | 1.76 | 3.36 | 2.03 |
Pretax Income | -73.79 | -91.98 | -77.57 | 42.11 | 15.79 | 9.57 |
Income Tax Expense | 0.88 | -0.07 | 3.59 | 5.46 | 5.86 | 6.37 |
Earnings From Continuing Operations | -74.67 | -91.91 | -81.16 | 36.65 | 9.93 | 3.2 |
Net Income to Company | -74.67 | -91.91 | -81.16 | 36.65 | 9.93 | 3.2 |
Minority Interest in Earnings | -2.15 | -1.94 | -1.15 | -1.81 | 0.56 | - |
Net Income | -76.82 | -93.85 | -82.31 | 34.84 | 10.49 | 3.2 |
Net Income to Common | -76.82 | -93.85 | -82.31 | 34.84 | 10.49 | 3.2 |
Net Income Growth | - | - | - | 232.25% | 227.65% | -44.56% |
Shares Outstanding (Basic) | 542 | 521 | 514 | 498 | 524 | 457 |
Shares Outstanding (Diluted) | 542 | 521 | 514 | 498 | 524 | 457 |
Shares Change (YoY) | 5.79% | 1.35% | 3.35% | -5.07% | 14.68% | -4.96% |
EPS (Basic) | -0.14 | -0.18 | -0.16 | 0.07 | 0.02 | 0.01 |
EPS (Diluted) | -0.14 | -0.18 | -0.16 | 0.07 | 0.02 | 0.01 |
EPS Growth | - | - | - | 250.00% | 185.71% | -41.67% |
Free Cash Flow | -17.37 | -8.12 | -28 | -23.51 | -29.63 | 25.45 |
Free Cash Flow Per Share | -0.03 | -0.02 | -0.05 | -0.05 | -0.06 | 0.06 |
Gross Margin | 23.14% | 25.20% | 24.30% | 27.56% | 25.46% | 24.60% |
Operating Margin | -6.64% | -4.47% | -5.79% | 5.34% | 2.22% | 0.75% |
Profit Margin | -24.30% | -27.57% | -22.30% | 7.58% | 2.47% | 1.20% |
Free Cash Flow Margin | -5.50% | -2.38% | -7.58% | -5.11% | -6.98% | 9.51% |
EBITDA | -8.01 | -1.85 | -7.47 | 37.55 | 22.44 | 13.39 |
EBITDA Margin | -2.53% | -0.54% | -2.02% | 8.17% | 5.28% | 5.00% |
D&A For EBITDA | 12.97 | 13.36 | 13.88 | 13.02 | 13.02 | 11.38 |
EBIT | -20.98 | -15.21 | -21.35 | 24.53 | 9.42 | 2.01 |
EBIT Margin | -6.64% | -4.47% | -5.79% | 5.34% | 2.22% | 0.75% |
Effective Tax Rate | - | - | - | 12.97% | 37.13% | 66.56% |
Revenue as Reported | 316.06 | 340.47 | 369.15 | 459.68 | 424.72 | 267.7 |
Advertising Expenses | - | 2.97 | 2.2 | 1.04 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.